PubMed
MOTS-c is an ancient mitochondrial-encoded regulator of metabolic homeostasis
Lee C, Zeng J, Drew BG, et al. Cell Metab. 2015
Compare
MOTS-c vs PT-141
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
MOTS-c
113 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 18% · Mixed 2% · Unfavorable overall 80%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
230
Energy
47
Recovery
3
Mood
2
Cognition
1
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
191
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 5+ mg
Reports span 0.01 to ≥ 5 mg (open-ended top bucket)
0.01–0.025 mg
4
0.1–0.2 mg
1
0.2–0.4 mg
8
0.4–0.6 mg
11
0.6–1 mg
8
1–2 mg
42
2–3 mg
45
3–5 mg
7
5+ mg
107
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 56% said they felt similar to their last entry, 31% more positive, and 13% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 44 days · Based on 45 repeat reporters
PT-141
29 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 4% · Mixed 3% · Unfavorable overall 93%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Libido
115
Mood
2
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
38
Headache
37
Injection site irritation
35
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 2–3 mg
Reports span 0.1 to ≥ 5 mg (open-ended top bucket)
0.1–0.2 mg
1
0.2–0.4 mg
2
0.4–0.6 mg
9
0.6–1 mg
3
1–2 mg
9
2–3 mg
90
5+ mg
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 87% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 100 days · Based on 23 repeat reporters
Sources (11)
Published sources linked on the MOTS-c and PT-141 wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
MOTS-c: A mitochondrial-encoded peptide regulating muscle function
Reynolds JC, Lai RW, Woodhead JST, et al. Nat Commun. 2021
- Wiki study page →Source
PubMed
MOTS-c improves insulin sensitivity in mice and humans
Kim SJ, Xiao J, Wan J, et al. Aging Cell. 2019
- Wiki study page →Source
ClinicalTrials.gov
MOTS-c metabolic studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation
Zheng Y, Wei Z, Wang T. Frontiers in endocrinology. 2023
- Wiki study page →Source
PubMed
MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism
Lee C, Kim KH, Cohen P. Free radical biology & medicine. 2016
- Wiki study page →Source
FDA Drug Label
VYLEESI (bremelanotide injection) for subcutaneous use - Prescribing Information
AMAG Pharmaceuticals. FDA Drug Label. 2019
- Wiki study page →Source
PubMed
Bremelanotide: New Drug for Treating Hypoactive Sexual Desire Disorder
Kingsberg SA, Clayton AH, Portman D, et al. Obstet Gynecol. 2019
- Wiki study page →Source
ClinicalTrials.gov
Bremelanotide (PT-141) studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment
Pettigrew JA, Novick AM. Journal of midwifery & women's health. 2021
- Wiki study page →Source
PubMed
Pharmacologic therapeutic options for sexual dysfunction
Burton CS, Mishra K. Current opinion in obstetrics & gynecology. 2022